Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects With Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Next Previous
Trial Profile

Single-arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects With Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valemetostat (Primary)
  • Indications Acute myeloid leukaemia; Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms VALENTINE-PTCL01
  • Sponsors Daiichi Sankyo Inc

Most Recent Events

  • 02 Dec 2024 According to a Daiichi Sankyo Company media release, an exploratory analysis of circulating tumor DNA, a novel biomarker, to potentially predict clinical response to valemetostat from the VALENTINE-PTCL01 phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma, was recently presented in The Lancet Oncology.
  • 02 Dec 2024 According to a Daiichi Sankyo Company media release, data from this trial will be presented in a Poster session on Monday, December 9, 6:00 - 8:00 pm at American Society of Hematology (#ASH24) Annual Meeting.
  • 24 Jun 2024 According to a Daiichi Sankyo Company media release, company announced that EZHARMIA (valemetostat tosilate) has been approved in Japan for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) based on the results of the VALENTINE-PTCL01 phase 2 trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top